PCI Biotech Holding ASA PCIB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NOK 1.67
- Day Range
- NOK 1.51–1.69
- 52-Week Range
- NOK 1.20–3.40
- Bid/Ask
- NOK 1.41 / NOK 1.90
- Market Cap
- NOK 61.59 Mil
- Volume/Avg
- 121,887 / 86,404
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.pcibiotech.com
Valuation
|
Metric
|
PCIB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.58 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PCIB
|
|---|---|
Quick Ratio | 8.72 |
Current Ratio | 8.80 |
Interest Coverage | −139.89 |
Quick Ratio
PCIB
Profitability
|
Metric
|
PCIB
|
|---|---|
Return on Assets (Normalized) | −33.74% |
Return on Equity (Normalized) | −37.56% |
Return on Invested Capital (Normalized) | −41.02% |
Return on Assets
PCIB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rpngddvw | Nlp | $605.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nmtttnl | Nshtff | $116.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mdrmslcb | Jbrglz | $108.5 Bil | |
MRNA
| Moderna Inc | Hbzptshfv | Lqg | $62.9 Bil | |
BNTX
| BioNTech SE ADR | Rgzvprscv | Rbqy | $23.9 Bil | |
ARGX
| argenx SE ADR | Mgrksdcg | Zjct | $21.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ztdgnnkbt | Cdlztr | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fpnmvdp | Hnbzykm | $14.3 Bil | |
INCY
| Incyte Corp | Wzjxrxsp | Qscwzn | $12.9 Bil | |
UTHR
| United Therapeutics Corp | Rdxpmvtc | Xwq | $12.1 Bil |